首页> 外文期刊>Case Reports in Neurology >Childhood Stiff-Person Syndrome Improved with Rituximab
【24h】

Childhood Stiff-Person Syndrome Improved with Rituximab

机译:利妥昔单抗改善儿童僵硬综合征

获取原文
       

摘要

Introduction: Stiff-person syndrome (SPS) is manifested by fluctuating rigidity of axial musculature with painful episodic spasms due to simultaneous co-contraction of agonist and antagonist muscles. We present a case report and video illustrating response to treatment with rituximab. Materials and Methods: Case description and video are provided. A literature search for other reports of treatment with rituximab was performed. Results: Nine cases in addition to our case were described. Substantial clinical benefit was reported in 7/9 (78%) cases. Four out of 9 (44%) cases displayed persistent anti-glutamic acid decarboxylase (GAD) antibody positivity. Conclusion: Rituximab is an important treatment strategy in SPS. The persistence of anti-GAD antibody positivity even with clinical remission remains to be elucidated.
机译:简介:僵硬人综合征(SPS)表现为由于激动剂和拮抗肌同时收缩,轴向肌肉组织僵硬,并伴有阵发性痉挛。我们提供了一个病例报告和视频,说明对利妥昔单抗治疗的反应。资料和方法:提供了案例描述和视频。进行文献检索以寻找利妥昔单抗治疗的其他报告。结果:除本病例外,还描述了9例。在7/9(78%)病例中报告了可观的临床获益。 9个病例中有4个(44%)表现出持续的抗谷氨酸脱羧酶(GAD)抗体阳性。结论:利妥昔单抗是SPS的重要治疗策略。即使临床缓解,抗GAD抗体阳性的持久性仍有待阐明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号